A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/21/2002	WO2002062343A3 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/21/2002	WO2002057290A3 Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes
11/21/2002	WO2002053528A8 Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
11/21/2002	WO2002049649A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
11/21/2002	WO2002043765A3 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
11/21/2002	WO2002043718A3 Chemotherapeutic agents for the treatment of angiogenic diseases
11/21/2002	WO2002036171A9 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
11/21/2002	WO2002031201A3 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
11/21/2002	WO2002024226A8 Photosensitisers
11/21/2002	WO2002022598A8 Quinolinone derivatives as tyrosine kinase inhibitors
11/21/2002	WO2002022169A3 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
11/21/2002	WO2002018637A3 Diagnosis and treatment of prostate cancer
11/21/2002	WO2002016438A3 Synthesis of complex carbohydrates
11/21/2002	WO2002012250B1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
11/21/2002	WO2002011705A3 Composition for combined use of aromatase inhibitors
11/21/2002	WO2002000730A3 Pd-l2 molecules: novel pd-1 ligands and uses therefor
11/21/2002	WO2001087350A3 Treatment of human papillomavirus (hpv)-infected cells
11/21/2002	WO2001019397A9 Methods and compositions utilizing rad51
11/21/2002	WO2001017559A9 Semaphorin modulation of immune cell migration
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173658 Administering to a mammal a substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines to reduce the levels of tumor necrosis factor-alpha to treat autoimmune diseases
11/21/2002	US20020173655 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal
11/21/2002	US20020173654 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents
11/21/2002	US20020173646 Quinazoline derivatives and pharmaceutical compositions containing them
11/21/2002	US20020173641 Nucleotide sequences coding polypeptides for use in human therapeutics, pharmacology and diagnostics
11/21/2002	US20020173638 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of ovarian cancer
11/21/2002	US20020173586 Thermogelling biodegradable aqueous polymer solution
11/21/2002	US20020173543 Compounds for altering mitochondrial function and cellular responses
11/21/2002	US20020173540 Using plant extract
11/21/2002	US20020173534 Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
11/21/2002	US20020173533 Induce apoptosis; dissolving in critical fluid; separation
11/21/2002	US20020173532 Induce apoptosis
11/21/2002	US20020173531 Central nervous system disorders; psychological disorders
11/21/2002	US20020173528 Agonists specific for the peripheral cannabinoid receptor
11/21/2002	US20020173527 Tumor necrosis factor antagonist; antiinflammatory agents
11/21/2002	US20020173526 Heterocyclic compounds their production and use
11/21/2002	US20020173507 Antiproliferative agents; apoptosis; anticancer agents
11/21/2002	US20020173506 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists
11/21/2002	US20020173500 Hypotensive agents; antiischemic agents
11/21/2002	US20020173499 Estrogen replacement therapy
11/21/2002	US20020173488 Boronic Ester and acid compounds, synthesis and uses
11/21/2002	US20020173482 Antitumor, anticancer agents
11/21/2002	US20020173471 Anticancer agents
11/21/2002	US20020173470 Jasmonate pharmaceutical composition for treatment of cancer
11/21/2002	US20020173468 Modified cytostatic agents
11/21/2002	US20020173461 Methods for enhancing the efficacy of cancer therapy
11/21/2002	US20020173458 Polypeptides; genetic engineering
11/21/2002	US20020173449 O-superfamily conotoxin peptides
11/21/2002	US20020173445 Selective androgen receptor modulators and methods for their identification, design and use
11/21/2002	US20020173049 Controlling protein levels in eucaryotic organisms
11/21/2002	US20020173022 Polypeptide for use in the diagnosis, prevention and treatment of inflammation and disorders associated with cell proliferation and apoptosis
11/21/2002	US20020172999 Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
11/21/2002	US20020172991 Methods and kits for detecting protein kinases
11/21/2002	US20020172959 Compositions and methods relating to lung specific genes and proteins
11/21/2002	US20020172682 Using heat shock proteins to increase immune response
11/21/2002	US20020172680 Diagnosis of metastatic cancer by the mts-1 gene
11/21/2002	US20020172678 For regulating cellular proliferation and chemotaxis
11/21/2002	US20020172661 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta (IFN-beata)
11/21/2002	US20020172660 For therapy of cancer, viral infections
11/21/2002	DE10123503A1 Use of Belamcanda chinensis extract, or its active ingredient, for treating sex hormone-dependent urogenital disorders and prostatic hyperplasia
11/21/2002	CA2826627A1 Specific binding proteins and uses thereof
11/21/2002	CA2740056A1 Methods and compositions for treating mammalian nerve tissue injuries
11/21/2002	CA2460603A1 Unigene unidirectional antisense library
11/21/2002	CA2449188A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors
11/21/2002	CA2447574A1 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
11/21/2002	CA2447564A1 Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
11/21/2002	CA2447518A1 Therapeutic use of rank antagonists
11/21/2002	CA2447513A1 Compositions and methods for treating tumors bearing hmfg and cea antigens
11/21/2002	CA2447444A1 Antisense permeation enhancers
11/21/2002	CA2447431A1 Inhibitors of receptor activator of nf-kb and uses thereof
11/21/2002	CA2447292A1 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	CA2447287A1 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy
11/21/2002	CA2447286A1 Random gene unidirectional antisense library
11/21/2002	CA2447275A1 Therapeutic delivery of carbon monoxide
11/21/2002	CA2447139A1 Specific binding proteins and uses thereof
11/21/2002	CA2447052A1 Combined approach to treatment of cancer using a c-myc antisense oligomer
11/21/2002	CA2447050A1 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
11/21/2002	CA2447004A1 Antisense modulation of ptp1b expression
11/21/2002	CA2446991A1 Agents that regulate apoptosis
11/21/2002	CA2446956A1 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer
11/21/2002	CA2446879A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	CA2446806A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
11/21/2002	CA2446740A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	CA2446736A1 Chemoprotection using amifostine and related compounds
11/21/2002	CA2446717A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	CA2446589A1 Methods for treating cancer
11/21/2002	CA2446586A1 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	CA2445922A1 Estrogen receptor modulators
11/21/2002	CA2445477A1 Antitumor agents
11/21/2002	CA2445366A1 Molecules for disease detection and treatment
11/21/2002	CA2443627A1 Genes expressed in breast cancer as prognostic and therapeutic targets
11/21/2002	CA2429718A1 Human and non-human primate homologues of nkd protein, nucleic acid sequences encoding, and uses thereof
11/20/2002	EP1258490A1 Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates
11/20/2002	EP1258484A1 Novel isoxazole and thiazole compounds and use thereof as drugs
11/20/2002	EP1258474A2 Alkylamide compounds
11/20/2002	EP1258255A1 Conjugates of an antibody to CD44 and a maytansinoid
11/20/2002	EP1258252A1 Integrin expression inhibitors
11/20/2002	EP1258248A2 Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent
11/20/2002	EP1257822A1 Her-2 binding antagonists
11/20/2002	EP1257669A1 Antisense modulation of e2f transcription factor 3 expression

1 ... 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 ... 2211